Prostate Cancer UK/Movember Funded Post-Doctoral position in Bioinformatics for Prostate Cancer
The University of Manchester - CRUK Manchester Institute
- Richard Marais: Molecular Oncology Group and Caroline Dive: Clinical and Experimental Pharmacology
- Fixed term position until 30 June 2017
The CRUK Manchester Institute (www.cruk.manchester.ac.uk) in the UK is a centre for excellence in cancer research. We occupy state-of-the-art laboratories and provide exceptional core facilities, including next generation sequencing, mass-spectrometry, advanced imaging, bioinformatics, histology, and flow cytometry. We are core-funded by Cancer Research UK (www.cancerresearchuk.org), the world’s largest cancer organisation, are an Institute of The University of Manchester (www.manchester.ac.uk), and are juxtaposed to The Christie NHS Foundation Trust (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes in a vibrant and dynamic city surrounded by beautiful countryside and with excellent national and international transport links.
Together with Queen’s University Belfast, we have recently been awarded a Movember Centre of Excellence for prostate cancer research. Three positions are available for post-doctoral scientists to join the Molecular Oncology Group led by Prof Richard Marais, Director of the Institute, and in the Clinical and Experimental Pharmacology Group led by Professor Caroline Dive, Deputy Director of the Institute. Prof Marais has made important contributions to our understanding of the biology and genetics of melanoma (Cell 140: 209, 2010; Cancer Cell 15: 294, 2009 and 19, 2011: 45; Cancer Research 70: 8036, 2010, NEJM 366: 207-215, 2012; Genome Research 22: 196-207, 2012). Prof Dive’s laboratory has an international reputation for circulating biomarker research notably relating to the utility of circulating tumour cells in personalised medicine (J Clinical Oncology 29:1556, 2011, J Clinical Oncology 30: 525, 2012, J Thoracic Oncology 7, 306, 2012, J Investigative Dermatology 133: 1582 2013, Nature Reviews Clinical Oncology 15: 30 2014).
The successful candidate will join a team who will implement personalised medicine for prostate cancer. The post holder will be responsible for working with other team members to integrate genomics and proteomics data from patient samples. They will collaborate to advance the data for practical use in the personalised medicine platform and to pursue follow-up studies as appropriate. The successful candidate will hold a PhD in bioinformatics and relevant experience in cancer will be an advantage. The post holder will be jointly managed by Professor Marais and Professor Dive.
To apply for this position please visit our website: www.cruk.manchester.ac.uk
For applicants who are unable to download this information from our website, please contact HR department on 0161 446 3231, email: email@example.com to have this information sent by post.
The deadline for receipt of applications is 13th March 2015.